首页> 外文OA文献 >Epitope-loaded nanoemulsion delivery system with ability of extending antigen release elicits potent Th1 response for intranasal vaccine against Helicobacter pylori
【2h】

Epitope-loaded nanoemulsion delivery system with ability of extending antigen release elicits potent Th1 response for intranasal vaccine against Helicobacter pylori

机译:延伸抗原释放能力的表位纳米乳剂递送系统具有鼻内疫苗对幽门螺杆菌鼻内疫苗的有效Th1反应

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Abstract Background Helicobacter pylori (H. pylori) infection remains a global public health issue, especially in Asia. Due to the emergence of antibiotic-resistant strains and the complexity of H. pylori infection, conventional vaccination is the best way to control the disease. Our previous study found that the N-acetyl-neuroaminyllactose-binding hemagglutinin protein (HpaA) is an effective protective antigen for vaccination against H. pylori infection, and intranasal immunization with the immunodominant HpaA epitope peptide (HpaA 154-171, P22, MEGVLIPAGFIKVTILEP) in conjunction with a CpG adjuvant decreased bacterial colonization in H. pylori-infected mice. However, to confer more robust and effective protection against H. pylori infection, an optimized delivery system is needed to enhance the P22-specific memory T cell response. Results In this study, an intranasal nanoemulsion (NE) delivery system offering high vaccine efficacy without obvious cytotoxicity was designed and produced. We found that this highly stable system significantly prolonged the nasal residence time and enhanced the cellular uptake of the epitope peptide, which powerfully boosted the specific Th1 responses of the NE-P22 vaccine, thus reducing bacterial colonization without CpG. Furthermore, the protection efficacy was further enhanced by combining the NE-P22 vaccine with CpG. Conclusion This epitope-loaded nanoemulsion delivery system was shown to extend antigen release and elicit potent Th1 response, it is an applicable delivery system for intranasal vaccine against H. pylori.
机译:摘要背景幽门螺杆菌(幽门螺旋杆菌)感染仍然是一个全球性的公共健康问题,尤其是在亚洲。由于抗生素抗性菌株的出现和幽门螺旋杆菌感染的复杂性,传统的疫苗接种是控制疾病的最佳途径。我们先前的研究发现,N-乙酰基neuroaminyllactose结合血凝素蛋白(蛋白HpaA)可以对幽门螺杆菌感染的疫苗接种的有效的保护性抗原,和与免疫蛋白HpaA表位肽鼻内免疫(蛋白HpaA 154-171,P22,MEGVLIPAGFIKVTILEP)与CpG佐剂一起在幽门螺旋杆菌感染的小鼠降低细菌定植。然而,为了赋予抗幽门螺旋杆菌感染更鲁棒和有效的保护,需要一种优化的递送系统,以增强特定P22-记忆T细胞应答。结果在该研究中,鼻内纳米乳剂(NE)传送系统没有明显细胞毒性提供高疫苗功效的设计和生产。我们发现,这种高度稳定的系统显著延长鼻滞留时间,提高了表位肽的细胞吸收,从而有力地推动了NE-P22疫苗的特异性Th1反应,从而减少细菌定植没有的CpG。此外,保护效力进一步通过NE-P22疫苗的CpG结合增强。结论该表位的纳米乳剂装入输送系统被示出为延伸抗原释放并引发有效的Th1应答,它是对幽门螺杆菌疫苗鼻内适用的递送系统。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号